Mesa Laboratories
Supplies sterilization, biopharma, calibration, and clinical-genomics tools for regulated health markets.
Something off on this page? Send us feedback.
Profile
Sells life-science tools and quality-control solutions across sterilization and disinfection control, biopharmaceutical development, calibration, and clinical genomics. Revenue comes from consumables, instruments, software, services, and lab testing, with sterilization indicators and calibration tools forming the largest current pillars.
Designs and manufactures life-science tools and critical quality-control solutions for regulated pharmaceutical, healthcare, and medical-device customers. The operating structure spans Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics.
Sales move through direct teams in North America, Europe, and APAC plus independent distributors globally. The portfolio includes biological and chemical sterilization indicators, lab testing services, automated protein-analysis and peptide-synthesis systems, calibration and monitoring tools, and genetic-analysis products.
Most current weight sits in sterilization indicators and calibration solutions, while Clinical Genomics is exposed to China demand and trade conditions. The business depends on regulated customer workflows where product quality, suitability for use, cost effectiveness, and channel reach matter.
Company facts
Key statistics
Year to date +62.5% · Average volume (30d) 151.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Wells Fargo | Reiterate | Equal Weight | $94 | $110 | |
| Feb 4, 2026 | Wells Fargo | Reiterate | Equal Weight | $83 | $94 | |
| Dec 15, 2025 | Wells Fargo | Reiterate | Equal Weight | $120 | $83 | |
| Aug 8, 2025 | Wells Fargo | Upgrade | Underweight | Equal Weight |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026Q1 FY27 | $2.63 | $2.68 | +1.9% | $60.9M | $60.1M | −1.2% | +9.46% |
| May 27, 2026Q4 FY26 | $2.09 | $2.76 | +32.1% | $65.2M | $63.7M | −2.3% | +13.55% |
| Feb 3, 2026Q3 FY26 | $1.40 | $3.07 | +119.3% | $63.2M | $65.1M | +3.0% | +4.57% |
| Nov 6, 2025Q2 FY26 | $1.56 | $1.76 | +12.8% | $61.0M | $60.7M | −0.5% | +1.52% |
Financial highlights
| 12 quarters | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|
| Revenue | $62.1M | $59.5M | $60.7M | $65.1M | $63.7M | $60.1M | |
| Gross profit | $38.4M | $32.5M | $37.3M | $41.8M | $46.7M | $39.0M | |
| Operating income | $1.5M | $3.1M | $4.7M | $8.0M | $2.7M | $7.0M | |
| Net income | −$7.1M | $4.7M | $2.5M | $3.6M | −$4.1M | $2.8M | |
| Diluted EPS | −$1.31 | $0.85 | $0.45 | $0.65 | −$0.75 | $0.49 | |
| Gross margin | 61.8% | 54.6% | 61.5% | 64.2% | 73.2% | 64.9% | |
| Operating margin | 2.4% | 5.1% | 7.8% | 12.2% | 4.3% | 11.7% |
Fiscal years (4-quarter sums)FY22 $184.3M · FY23 $219.1M · FY24 $216.2M · FY25 $241.0M · FY26 $249.1M
Revenue by product · Q1 FY27
Revenue by geography · Q1 FY27
Balance sheet, Jun 30, 2026Cash & short-term investments $30.7M · Total debt $101.4M · Total assets $419.2M · Shareholders' equity $188.8M
Dividends
Raised for 21 straight years. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| May 29, 2026 | May 29 | Jun 15 | $0.16 | |
| Feb 27, 2026 | Feb 28 | Mar 16 | $0.16 | |
| Nov 28, 2025 | Nov 28 | Dec 15 | $0.16 | |
| Aug 29, 2025 | Aug 29 | Sep 15 | $0.16 | |
| May 30, 2025 | May 30 | Jun 16 | $0.16 | |
| Feb 28, 2025 | Feb 28 | Mar 17 | $0.16 | |
| Nov 29, 2024 | Nov 29 | Dec 16 | $0.16 | |
| Aug 30, 2024 | Aug 30 | Sep 16 | $0.16 |
Ownership
Shares outstanding 5.60M · Float 4.90M · 87.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Conestoga Capital Advisors | 618.1K | 11.38% | 13G | Jan 10, 2025 |
| Long Path Partners LP | 477.1K | 8.53% | 13F | Jul 31, 2026 |
| BlackRock, Inc. | 440.6K | 7.87% | 13F | Aug 7, 2026 |
| Boston Partners | 265.1K | 4.74% | 13F | Aug 4, 2026 |
| Vanguard Capital Management LLC | 237.5K | 4.24% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | John James Sullivan | director | −7,093 | $112.80 |
| Aug 13, 2026 | Siddhartha Kadia | officer: President and CEO | +7,093 | $112.80 |
| Aug 13, 2026 | R. Tony Tripeny | director | +900 | $113.69 |
| Jun 22, 2026 | John Sakys | officer: CFO | −2,827 | $89.50 |
| Jun 22, 2026 | Brian David Archbold | officer: SVP Operations | −2,516 | $89.50 |
Peers
- STERIS
Sterilization-assurance rival with biological indicators and services
- Solventum
Attest sterilization monitoring competes with SDC indicator lines
- Fortive
Calibration and process-test rival through Fluke Calibration
- Thermo Fisher Scientific
Broad life-science tools rival in protein biology and genetic analysis
- Danaher
Life-science and diagnostics platform competing across BPD and genomics
- Bio-Rad Laboratories
Protein-analysis and digital-PCR rival for research and biopharma labs
- QIAGEN
Molecular testing and genomic-profiling rival to Clinical Genomics
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Mesa Laboratories | $126.67 | −1.86% | $722.4M | 153.7 | 15.7 | 2.9 | +1.0% |
| STERIS | $233.78 | +0.06% | $22.78B | 28.6 | 20.4 | 3.8 | +7.8% |
| Solventum | $90.50 | −0.68% | $15.78B | 11.1 | 13.5 | 1.9 | +2.2% |
| Fortive | $59.69 | 0.00% | $18.03B | 35.1 | 19.2 | 4.2 | −27.8% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Bio-Rad Laboratories | $387.70 | +0.02% | $10.44B | 47.0 | 37.6 | 4.0 | −0.1% |
| QIAGEN | $43.00 | −0.28% | $8.89B | 22.1 | 17.3 | 4.2 | +0.3% |
| Median | 33.5 | 20.4 | 4.2 | +2.2% |